<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124097</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-308</org_study_id>
    <secondary_id>2010-019101-42</secondary_id>
    <nct_id>NCT01124097</nct_id>
  </id_info>
  <brief_title>Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia</brief_title>
  <official_title>A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate
      (ESL) as therapy in subjects with Post-herpetic Neuralgia (PHN) over a 15 week treatment
      phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-herpetic neuralgia (PHN) is a syndrome of intractable pain following an acute infection
      of herpes zoster (shingles).

      Treatment for PHN is often suboptimal. More than 50% of the subjects fail to respond to
      pharmacological treatments or experience intolerable side effects.

      The clinical development of ESL to treat neuropathic pain is based on its chemical and
      pharmacodynamic relationship to sodium channel blockers, including carbamazepine, which is
      effective for treating some neuropathic pain conditions. Preclinical data supports the
      theoretical background.

      This study will examine the efficacy, safety, tolerability and pharmacokinetics of
      Eslicarbazepine acetate for the treatment of post herpetic neuralgia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Endpoint in Mean Pain</measure>
    <time_frame>baseline to endpoint</time_frame>
    <description>The efficacy analysis was restricted to the primary efficacy variable in the analysis population. The intended treatment period, starting on the day of the randomization and ending at the efficacy cut-off date (October 31, 2011), was the basis for the analysis.
The primary efficacy variable was the difference between the mean values of 7 daily pain scores preceding the efficacy cut-off date (endpoint mean pain score), and before randomization (baseline mean pain score), respectively. The daily pain scores were based on the morning response to the 11-point Numeric Rating Pain Scale (NRPS) question relating to average pain intensity over the last 24 hours. The NPRS is an 11-point scale from 0-10 [&quot;0&quot; = no pain; &quot;10&quot; = the most intense pain imaginable]</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Post Herpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>Eslicarbazepine acetate 800 mg once daily (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eslicarbazepine acetate 1200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eslicarbazepine acetate 1600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eslicarbazepine acetate (BIA 2-093)</intervention_name>
    <description>Tablets will be used.</description>
    <arm_group_label>Eslicarbazepine acetate 800 mg once daily (QD)</arm_group_label>
    <arm_group_label>Eslicarbazepine acetate 1200 mg QD</arm_group_label>
    <arm_group_label>Eslicarbazepine acetate 1600 mg QD</arm_group_label>
    <other_name>Exalief</other_name>
    <other_name>Zebinix</other_name>
    <other_name>BIA 2-093</other_name>
    <other_name>ESL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets will be used.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients aged 18 years or older. Female subjects are of
             nonchildbearing potential, defined as surgical sterilization (hysterectomy or
             bilateral oophorectomy or tubal ligation) or at least 2 years postmenopausal
             (spontaneous amenorrhea for at least 24 months before Visit 1), or if of childbearing
             potential, subjects agree to use a medically acceptable nonhormonal method of
             contraception.

          -  Experiencing pain for at least 6 months after the healing of a herpes zoster skin
             rash.

          -  A mean score between 4.0 and 9.0, inclusive, on the 24 hour average pain intensity
             assessment.

          -  Compliance with patient diary completion.

          -  If not used to treat PHN, subjects are permitted to take nonsteroidal anti
             inflammatory drugs and selective serotonin reuptake inhibitors if they were kept on a
             stable dose for 1 month prior to Screening and are foreseen to remain stable
             throughout the study.

          -  Competent and able to freely give own informed consent.

          -  Female subjects of childbearing potential, who are not currently breastfeeding, must
             have a negative serum pregnancy test at Visit 1.

        Exclusion Criteria:

          -  Historical exposure to drugs known to cause neuropathy

          -  Significant skin lesions (active infection, ulcer, etc).

          -  Known intolerance to ESL or to other carboxamide derivatives (eg, carbamazepine or
             oxcarbazepine) or frequent or severe allergic reactions with multiple medications.

          -  Subjects who previously participated in a clinical study with ESL.

          -  Major psychiatric disorder.

          -  Serious or unstable cardiovascular disease that could compromise participation or
             cause hospitalization during the study.

          -  Second or third degree atrioventricular blockade not corrected with a pacemaker or any
             clinically significant abnormality in the 12 lead electrocardiogram as determined by
             the investigator.

          -  Subjects taking the following drug classes and individual drugs are excluded:
             benzodiazepines (except short half life sleep agents), skeletal muscle relaxants,
             orally administered steroids, capsaicin, mexiletine, centrally acting analgesics
             (dextromethorphan, tramadol), opiates, topical lidocaine, anticonvulsants, tricyclic
             antidepressants, and serotonin norepinephrine reuptake inhibitors. These drugs require
             a minimum washout period of at least 5 times the half life and should be tapered
             appropriately using product label instructions as a guide.

          -  Relevant clinical laboratory abnormality that, in the investigator's opinion, can
             compromise the subject's safety.

          -  History of drug abuse or dependence (drug categories defined by DSM IV) within the
             past year, excluding nicotine and caffeine.

          -  Subjects who, in the previous 30 days, received treatment with a drug that had not
             received regulatory approval for any indication at the time of study entry.

          -  History of recurrent epileptic seizures except febrile seizures.

          -  History of severe gastroparesis or gastric bypass surgery.

          -  Neurolytic or neurosurgical treatment for PHN.

          -  Injected anesthetics or steroid use within 30 days of Visit 1.

          -  Malignancy within past 2 years.

          -  History of chronic hepatitis B or C within the past 3 months or human immunodeficiency
             virus infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Synexus ClinPharm GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <results_first_submitted>January 10, 2014</results_first_submitted>
  <results_first_submitted_qc>February 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2014</results_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post herpetic neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eighty nine (89) clinical sites in 12 countries
Study period:
Date of first admission: 2010.09.28 Date of last visit: 2012.04.23</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Esl 1600 mg QD</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="P2">
          <title>Esl 1200 mg QD</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="P3">
          <title>Esl 800 mg Once Daily (QD)</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: Tablets will be used.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Efficacy Population</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esl 1600 mg QD</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="B2">
          <title>Esl 1200 mg QD</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="B3">
          <title>Esl 800 mg Once Daily (QD)</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: Tablets will be used.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="60"/>
            <count group_id="B5" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="16.71"/>
                    <measurement group_id="B2" value="65.4" spread="14.47"/>
                    <measurement group_id="B3" value="65.9" spread="15.6"/>
                    <measurement group_id="B4" value="65.4" spread="14.43"/>
                    <measurement group_id="B5" value="64.9" spread="15.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Endpoint in Mean Pain</title>
        <description>The efficacy analysis was restricted to the primary efficacy variable in the analysis population. The intended treatment period, starting on the day of the randomization and ending at the efficacy cut-off date (October 31, 2011), was the basis for the analysis.
The primary efficacy variable was the difference between the mean values of 7 daily pain scores preceding the efficacy cut-off date (endpoint mean pain score), and before randomization (baseline mean pain score), respectively. The daily pain scores were based on the morning response to the 11-point Numeric Rating Pain Scale (NRPS) question relating to average pain intensity over the last 24 hours. The NPRS is an 11-point scale from 0-10 [“0” = no pain; “10” = the most intense pain imaginable]</description>
        <time_frame>baseline to endpoint</time_frame>
        <population>efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Esl 1600 mg QD</title>
            <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
          </group>
          <group group_id="O2">
            <title>Esl 1200 mg QD</title>
            <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
          </group>
          <group group_id="O3">
            <title>Esl 800 mg Once Daily (QD)</title>
            <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: Tablets will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Mean Pain</title>
          <description>The efficacy analysis was restricted to the primary efficacy variable in the analysis population. The intended treatment period, starting on the day of the randomization and ending at the efficacy cut-off date (October 31, 2011), was the basis for the analysis.
The primary efficacy variable was the difference between the mean values of 7 daily pain scores preceding the efficacy cut-off date (endpoint mean pain score), and before randomization (baseline mean pain score), respectively. The daily pain scores were based on the morning response to the 11-point Numeric Rating Pain Scale (NRPS) question relating to average pain intensity over the last 24 hours. The NPRS is an 11-point scale from 0-10 [“0” = no pain; “10” = the most intense pain imaginable]</description>
          <population>efficacy population</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.290"/>
                    <measurement group_id="O2" value="-1.34" spread="0.277"/>
                    <measurement group_id="O3" value="-0.94" spread="0.281"/>
                    <measurement group_id="O4" value="-0.77" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9321</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2610</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4764</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>participants were followed an average of 55 weeks (19 weeks DB + 36 weeks OL)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Esl 1600 mg QD</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="E2">
          <title>Esl 1200 mg QD</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="E3">
          <title>Esl 800 mg Once Daily (QD)</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093): Tablets will be used.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: Tablets will be used.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="60"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director R&amp;D</name_or_title>
      <organization>BIAL – Portela &amp; Cª S.A.</organization>
      <phone>+351-229866100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

